Destiny Pharma out-licenses NTCD-M3 to Sebela

25 February 2023
destiny-big

Shares of UK infectious disease specialist Destiny Pharma (AIM: DEST) closed down almost 25% at 36.10 pence on Friday, despite the company announcing a licensing deal that could earn it more that half a billion dollars, albeit heavily back-loaded.

Destiny has signed an exclusive collaboration and co-development agreement for the North American (USA, Canada and Mexico) rights of NTCD-M3, its lead asset for the prevention of Clostridioides difficile infection (CDI) recurrence, with USA-based Sebela Pharmaceuticals, a company with a market-leading position in gastroenterology.

The share price slump was caused by Destiny’s announcement of a share placement, but the deal with Sebela should de-risk the Phase III trial of the drug. The phase III trial will start next year and there could be a commercial launch in 2027 if everything goes to plan.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical